A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.

For decades, medical cancer treatment has generally meant chemotherapy, radiation, or surgery, alone or in combination. Today, new approaches such as immunotherapies and targeted therapies are becoming available, with many more in research and development.

Duke’s researchers had another banner year of successes, according to the 2021–2022 research annual report . School of Medicine faculty and funding played an important role.

The initial gift for the Duke Climate Commitment has provided funding for Climate and Health Data Expeditions, where interdisciplinary teams, pursue research on data-driven topics examining climate impacts and human health.

Post-menopausal women on hormone replacement therapy had a lower risk of developing a painful shoulder condition known as adhesive capsulitis compared to women who did not receive estrogen, according to a study led by Duke Health researchers.

L. Ebony Boulware, MD, MPH, Director of the Duke Clinical and Translational Science Institute (CTSI), will step down from her positions at Duke on December 31, 2022, to begin a new role as Dean of the Wake Forest University School of Medicine in January 2023.

Nicole Calakos, MD, PhD, a professor of neurology and Lincoln Financial Group Distinguished Professor of Neurobiology, has been elected to the U.S. National Academy of Medicine (NAM).  

Health challenges across the globe — everything from climate change to infectious disease and better treatment options for patients — precipitate the need for skilled physician-scientists: physicians who see patients in the clinic and who also devote time to scientific research. Duke programs including the Office of Physician-Scientist Development and the Medical Scientist Training Program are helping to meet that need.

2019 Nobel Prize winner Bill Kaelin says he’d be disappointed if he could predict the next big thing in cancer research and care, because many of the greatest advances come from unexpected directions.

Eugenie S. Kleinerman, chair of the Division of Pediatrics at the University of Texas MD Anderson Cancer Center, is exploring how to alter the tumor microenvironment to increase the efficacy of treatments and improve outcomes.